Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LTB4R | Q15722 | 12/20 | 0.56 |
| ▸ | LTB4R2 | Q9NPC1 | 12/20 | 0.56 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.41 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.37 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.35 |
| ▸ | GRM5 | P41594 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30251527 | 1.00 | LTB4R (0.56) | LTB4RLTB4R2MAOAMAOBPSMB5 | |
| SCHEMBL9121287 | 0.90 | LTB4R (0.50) | LTB4RLTB4R2MAOAMAOBESR1 | |
| SCHEMBL23882856 | 0.88 | LTB4R (0.46) | LTB4RLTB4R2MAOAMAOBPSMB5 | |
| SCHEMBL6561553 | 0.85 | PSMB5 (0.58) | LTB4RLTB4R2PSMB5ESR1ESR2 | |
| SCHEMBL8463571 | 0.80 | MAOB (0.49) | LTB4RLTB4R2MAOAMAOBGRM5 | |
| SCHEMBL9119318 | 0.77 | GRM5 (0.44) | LTB4RLTB4R2MAOAMAOBPSMB5 | |
| SCHEMBL30251104 | 0.76 | ESR1 (0.51) | LTB4RLTB4R2MAOAMAOBPSMB5 | |
| SCHEMBL12316602 | 0.76 | ESR1 (0.51) | LTB4RLTB4R2MAOAMAOBPSMB5 | |
| SCHEMBL20554846 | 0.73 | MAOB (0.47) | LTB4RLTB4R2MAOAMAOBPSMB5 | |
| SCHEMBL20554446 | 0.73 | MAOB (0.47) | LTB4RLTB4R2MAOAMAOBPSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4126835-B1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2026-02-18 | — | — | EP | disclosed |
| US-12516038-B2 | Inhibitors of antigen presentation by HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2026-01-06 | — | — | US | disclosed |
| US-20230150985-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2023-05-18 | — | — | US | disclosed |
| EP-4126835-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | Janssen Pharmaceutica NV (BE) | 2023-02-08 | — | — | EP | disclosed |
| WO-2021198283-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | JANSSEN PHARMACEUTICA NV (BE) | 2021-10-07 | — | — | WO | disclosed |
| US-5434186-A | Antiinflammatory agents | HOFFMANN-LA ROCHE INC. (US) | 1995-07-18 | — | — | US | disclosed |
| US-5273999-A | A 4-keto-boroalkyleneoxychroman or 2,3-dihydrobenzofuran derivative | HOFFMANN-LA ROCHE INC. (US) | 1993-12-28 | — | — | US | disclosed |
| EP-0531823-A1 | Bicyclic carboxylic acid derivatives as anti-inflammatory agents | F. HOFFMANN-LA ROCHE AG (CH) | 1993-03-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230150985-A1 | INHIBITORS OF ANTIGEN PRESENTATION BY HLA-DR | HLA-DRB1, CD74, HLA-C | LTB4R 562/4885LTB4R2 644/4885MAOA 1864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.